Tokarski JS (2006). “The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.”. Cancer Res.66 (11): 5790-5797. doi:10.1158/0008-5472.CAN-05-4187. PMID16740718.
nih.gov
pubmed.ncbi.nlm.nih.gov
Tokarski JS (2006). “The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.”. Cancer Res.66 (11): 5790-5797. doi:10.1158/0008-5472.CAN-05-4187. PMID16740718.